We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

1st Circ. Revives Investors' Feraheme Risks Class Action

Law360, New York (February 5, 2013, 3:25 PM EST) -- The First Circuit on Monday revived a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks associated with iron deficiency treatment Feraheme, ruling the investors had made a reasonable claim that AMAG had failed to disclose relevant information on those risks.

According to a three-judge panel, the investors — led by Silverstrand Investments LLC, Safron Capital Corp. and Briarwood Investments Inc. — had made a plausible claim that AMAG had wrongly failed to tell investors about 23 serious...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.